Diagnostic accuracy of markers for prodromal Alzheimer's disease in independent clinical series

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Alzheimer's & Dementia

• Publication date

  2013-11-01

• Fields of study

  Medicine, Psychology

• Identifiers
  DOI 10.1016/j.jalz.2012.09.016PMID 23375562PMCID PMC4058442
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Summary Metrics to Assess Alzheimer Disease–Related Hypometabolic Pattern with 18F-FDG PET: Head-to-Head Comparison

  2012cited by this paper
• Operationalizing diagnostic criteria for Alzheimer's disease and other age‐related cognitive impairment—Part 1

  2011cited by this paper
• Hippocampal Sclerosis in the Elderly: Genetic and Pathologic Findings, Some Mimicking Alzheimer Disease Clinically

  2011cited by this paper
• The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

  2011cited by this paper
• Clinical diagnosis of Alzheimer's disease: Report of the NINCDS—ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease

  2011cited by this paper
• Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

  2011cited by this paper
• The diagnosis of mild cognitive impairment due to Alzheimer's disease: Recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

  2011cited by this paper
• Amyloid β (Aβ) and phospho-tau (p-tau) as diagnostic biomarkers in Alzheimer's disease

  2011cited by this paper
• Operationalizing diagnostic criteria for Alzheimer's disease and other age‐related cognitive impairment—Part 2

  2011cited by this paper
• Cerebrospinal Fluid Biomarkers for Alzheimer's Disease: Diagnostic Performance in a Homogeneous Mono-Center Population

  2011cited by this paper
• Associations between cognitive, functional, and FDG-PET measures of decline in AD and MCI.

  2011cited by this paper
• Characterizing Alzheimer's disease using a hypometabolic convergence index

  2011cited by this paper
• The Alzheimer's Disease Neuroimaging Initiative positron emission tomography core

  2010cited by this paper
• A Comparison of the Diagnostic Sensitivity of MRI, CBF-SPECT, FDG-PET and Cerebrospinal Fluid Biomarkers for Detecting Alzheimer’s Disease in a Memory Clinic

  2010cited by this paper
• Manual validation of FreeSurfer's automated hippocampal segmentation in normal aging, mild cognitive impairment, and Alzheimer Disease subjects.

  2010influential reference
• Metabolic Compensation and Depression in Alzheimer’s Disease

  2010cited by this paper
• Combining MR Imaging, Positron-Emission Tomography, and CSF Biomarkers in the Diagnosis and Prognosis of Alzheimer Disease

  2010cited by this paper
• The clinical use of structural MRI in Alzheimer disease

  2010cited by this paper
• Revising the definition of Alzheimer's disease: a new lexicon.

  2010cited by this paper
• Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade.

  2010cited by this paper
• Whole-brain atrophy rate and CSF biomarker levels in MCI and AD: a longitudinal study.

  2010cited by this paper
• CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment.

  2009cited by this paper
• A comparison of automated segmentation and manual tracing for quantifying hippocampal and amygdala volumes

  2009cited by this paper
• In Vivo Hippocampal Measurement and Memory: A Comparison of Manual Tracing and Automated Segmentation in a Large Community-Based Sample

  2009cited by this paper
• Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects

  2009cited by this paper
• Markers of Alzheimer's disease in a population attending a memory clinic

  2009cited by this paper
• The Italian Brain Normative Archive of structural MR scans: norms for medial temporal atrophy and white matter lesions

  2009cited by this paper
• MRI and CSF biomarkers in normal, MCI, and AD subjects

  2009cited by this paper
• The Alzheimer's disease neuroimaging initiative (ADNI): MRI methods

  2008influential reference
• Brain perfusion correlates of medial temporal lobe atrophy and white matter hyperintensities in mild cognitive impairment

  2007cited by this paper
• Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria.

  2007cited by this paper
• MR-based in vivo hippocampal volumetrics: 1. Review of methodologies currently employed

  2005cited by this paper
• Comparison of automated and manual MRI volumetry of hippocampus in normal aging and dementia

  2002cited by this paper
• Discrimination between Alzheimer Dementia and Controls by Automated Analysis of Multicenter FDG PET

  2002cited by this paper
• Neurotechnique Whole Brain Segmentation: Automated Labeling of Neuroanatomical Structures in the Human Brain

  2002cited by this paper
• Tau and Abeta42 in cerebrospinal fluid from healthy adults 21-93 years of age: establishment of reference values.

  2001cited by this paper
• Volumetry of hippocampus and amygdala with high-resolution MRI and three-dimensional analysis software: minimizing the discrepancies between laboratories.

  2000cited by this paper
• Mild Cognitive Impairment Clinical Characterization and Outcome

  1999cited by this paper
• Medial temporal atrophy on MRI in normal aging and very mild Alzheimer's disease

  1997influential reference
• Volumetric transformation of brain anatomy

  1997cited by this paper
• Clinical diagnosis of Alzheimer's disease

  1984cited by this paper

• Dual-path mixture of experts for Alzheimer's diagnosis using volume and entropy MRI features.

  2026cites this paper
• Learning‐Based Progression Detection of Alzheimer’s Disease Using 3D MRI Images

  2025cites this paper
• Effectiveness of brain magnetic resonance imaging in the early diagnosis and characterization of dementias: A systematic review

  2024cites this paper
• Effectiveness of brain magnetic resonance imaging in the early diagnosis and characterization of dementias; a systematic review.

  2024cites this paper
• The use of individual-based FDG-PET volume of interest in predicting conversion from mild cognitive impairment to dementia

  2024cites this paper
• How far is the goal of applying β-amyloid in cerebrospinal fluid for clinical diagnosis of Alzheimer's disease with standardization of measurements?

  2022cites this paper
• The impact of genetic risk for Alzheimer’s disease on the structural brain networks of young adults

  2021cites this paper
• Surface plasmon resonance biosensor for the detection of tau-amyloid β complex

  2020cites this paper
• Medial Temporal Atrophy Alone is Insufficient to Predict Underlying Alzheimer’s Disease Pathology

  2020cites this paper
• The Entorhinal Cortex Atrophy Score Is Diagnostic and Prognostic in Mild Cognitive Impairment

  2020cites this paper
• Structural magnetic resonance imaging for the early diagnosis of dementia due to Alzheimer's disease in people with mild cognitive impairment.

  2020cites this paper
• Association of muscle and visceral adipose tissues with the probability of Alzheimer’s disease in healthy subjects

  2019cites this paper
• Reciprocal Incremental Value of 18F-FDG-PET and Cerebrospinal Fluid Biomarkers in Mild Cognitive Impairment Patients Suspected for Alzheimer’s Disease and Inconclusive First Biomarker

  2019cites this paper
• Staging the cognitive continuum in prodromal Alzheimer's disease with episodic memory.

  2019cites this paper
• Prognostic value of Alzheimer’s biomarkers in mild cognitive impairment: the effect of age at onset

  2019cites this paper
• Mild Cognitive Impairment - concepts, cut-offs, and clinical relevance

  2019influential citation
• Dual-Model Radiomic Biomarkers Predict Development of Mild Cognitive Impairment Progression to Alzheimer’s Disease

  2019cites this paper
• Predicting progression from mild cognitive impairment to Alzheimer’s disease on an individual subject basis by applying the CARE index across different independent cohorts

  2019cites this paper
• Structural and Functional Brain Connectivity in Middle-Aged Carriers of Risk Alleles for Alzheimer's Disease

  2018cites this paper
• FDG-PET and CSF biomarker accuracy in prediction of conversion to different dementias in a large multicentre MCI cohort

  2018cites this paper
• Disrupted topology of the resting state structural connectome in middle‐aged APOE &egr;4 carriers

  2018cites this paper
• Age-Specific Cutoff Scores on a T1-Weighted Axial Medial Temporal-Lobe Atrophy Visual Rating Scale in Alzheimer's Disease Using Clinical Research Center for Dementia of South Korea Data

  2018cites this paper
• 18F-FDG PET for Prediction of Conversion to Alzheimer’s Disease Dementia in People with Mild Cognitive Impairment: An Updated Systematic Review of Test Accuracy

  2018cites this paper
• Controlled feature selection and compressive big data analytics: Applications to biomedical and health studies

  2018cites this paper
• Gait characteristics as indicators of cognitive impairment in geriatric patients: Karakteristieken van het lopen als indicatoren van cognitieve achteruitgang in geriatrische patiënten

  2018cites this paper
• The Erlangen Score Algorithm in the diagnosis and prediction of the progression from subjective cognitive decline and mild cognitive impairment to Alzheimer-type dementia.

  2018cites this paper
• Brain perfusion SPECT analysis: New insights in mild cognitive impairment and neuromyelitis optica

  2018influential citation
• Clinical validity of brain fluorodeoxyglucose positron emission tomography as a biomarker for Alzheimer's disease in the context of a structured 5-phase development framework.

  2017cites this paper
• Prediction of Mild Cognitive Impairment Conversion Using a Combination of Independent Component Analysis and the Cox Model

  2017cites this paper
• Clinical Amyloid Imaging.

  2017cites this paper
• Clinical validity of medial temporal atrophy as a biomarker for Alzheimer's disease in the context of a structured 5-phase development framework.

  2017cites this paper
• FDG-PET for Prediction of AD Dementia in Mild Cognitive Impairment. A Review of the State of the Art with Particular Emphasis on the Comparison with Other Neuroimaging Modalities (MRI and Perfusion SPECT).

  2017influential citation
• Molecular Imaging and Precision Medicine in Dementia and Movement Disorders.

  2017cites this paper
• Biomarkers for the diagnosis of Alzheimer's disease in clinical practice: an Italian intersocietal roadmap.

  2017cites this paper
• The impact of automated hippocampal volumetry on diagnostic confidence in patients with suspected Alzheimer's disease: A European Alzheimer's Disease Consortium study

  2017cites this paper
• Cerebral PET glucose hypometabolism in subjects with mild cognitive impairment and higher EEG high-alpha/low-alpha frequency power ratio.

  2017cites this paper
• Combined use of biochemical and volumetric biomarkers to assess the risk of conversion of mild cognitive impairment to Alzheimer's disease.

  2016cites this paper
• Walking ability to predict future cognitive decline in old adults: A scoping review.

  2016cites this paper
• Imagerie cérébrale de la maladie d’Alzheimer : état de l’art et perspectives pour le clinicien

  2016cites this paper
• Advances in PET Imaging of Degenerative, Cerebrovascular, and Traumatic Causes of Dementia.

  2016cites this paper
• Association between naturally occurring antiamyloid β autoantibodies and medial temporal lobe atrophy in Alzheimer's disease

  2016cites this paper
• The 4 Mountains Test: A Short Test of Spatial Memory with High Sensitivity for the Diagnosis of Pre-dementia Alzheimer's Disease

  2016cites this paper
• Varying Strength of Cognitive Markers and Biomarkers to Predict Conversion and Cognitive Decline in an Early-Stage-Enriched Mild Cognitive Impairment Sample

  2015cites this paper
• 2014 Update of the Alzheimer's Disease Neuroimaging Initiative: A review of papers published since its inception

  2015cites this paper
• Will PET amyloid imaging lead to overdiagnosis of Alzheimer dementia?

  2015cites this paper
• FDG-PET Contributions to the Pathophysiology of Memory Impairment

  2015cites this paper
• Future Prospects for Diagnostic Test Accuracy Studies in Dementia

  2015cites this paper
• Struktur und Funktion des episodischen und semantischen Gedächtnisses bei der sehr frühen Alzheimer Krankheit

  2015cites this paper
• Mild cognitive impairment with suspected nonamyloid pathology (SNAP)

  2015cites this paper
• The use of biomarkers for the etiologic diagnosis of MCI in Europe: An EADC survey

  2015cites this paper
• Comparison of Regional Gray Matter Atrophy, White Matter Alteration, and Glucose Metabolism as a Predictor of the Conversion to Alzheimer's Disease in Mild Cognitive Impairment

  2015cites this paper
• Reliability of a novel serious game using dual-task gait profiles to early characterize aMCI

  2015cites this paper
• Diagnostic Test Accuracy Studies in Dementia

  2015cites this paper
• Five-year biomarker progression variability for Alzheimer's disease dementia prediction: Can a complex instrumental activities of daily living marker fill in the gaps?

  2015cites this paper
• A Cochrane review on brain [18F]FDG PET in dementia: limitations and future perspectives

  2015cites this paper
• Predicting the Conversion from Mild Cognitive Impairment to Alzheimer ́s Disease using Evolution Patterns

  2014influential citation
• Multimodality Imaging of Alzheimer Disease and Other Neurodegenerative Dementias

  2014cites this paper
• Cerebrospinal fluid markers including trefoil factor 3 are associated with neurodegeneration in amyloid-positive individuals

  2014cites this paper
• Conflicting cerebrospinal fluid biomarkers and progression to dementia due to Alzheimer’s disease

  2014cites this paper
• Interactions between Amyloid-β and Tau in Cerebrospinal Fluid of People with Mild Cognitive Impairment and Alzheimer's Disease

  2014cites this paper
• The role of PET quantification in neurological imaging: FDG and amyloid imaging in dementia

  2014cites this paper
• Progress in clinical studies of dementia in 2013

  2014cites this paper
• The effect of 18F-florbetapir dose reduction on region-based classification of cortical amyloid deposition

  2014cites this paper
• Central effects of cholinesterase inhibitors in Alzheimer's disease: insights from advanced neuroimaging

  2013cites this paper
• Prediction of dementia in MCI patients based on core diagnostic markers for Alzheimer disease

  2013cites this paper
• Structural Covariance of the Default Network in Healthy and Pathological Aging

  2013cites this paper
• Computer-aided diagnostic reporting of FDG PET for the diagnosis of Alzheimer’s disease

  2013cites this paper
• Markers of dementia of Alzheimer ’ s type in cerebrospinal fluid

  year unknowncites this paper
• The use of an individual-based FDG-PET volume of interest approach in mild cognitive impairment: a multi-modality longitudinal follow-up study

  year unknowncites this paper